T. Chris Gamblin

Professor
Associate Chair
Ph.D., Vanderbilt University 1998
Primary office:
(785) 864-5065
5055 Haworth


Role of tau in Alzheimer's and other neurodegenerative disorders.

The presence of abnormal deposits of filamentous tau is thought to be a major part of the neurodegenerative process. For example, the location and amounts of tau pathology in specific regions of the brain correlates with the type and degree of observed dementia in patients. In addition, several mutations in the tau gene have been shown to be directly linked to increased tau pathology and neurodegeneration in familial cases of frontotemporal dementia.

Tau is a microtubule-associated protein that was originally discovered to associate with microtubules and provide stabilization for these structures. However, in the late 1980's, it was discovered that a "hyperphosphorylated" form of tau was the major component of several pathological structures in Alzheimer's disease known as neuropil threads, neurofibrillary tangles, and neuritic plaques. Further characterization of these structures revealed that the tau present in these structures had self-associated into filamentous structures known as straight filaments and paired-helical filaments. Since that time, numerous diseases have been identified as having significant tau pathology such as Pick's disease, progressive supranuclear palsy, and corticobasal degeneration.

The major goal of this laboratory is to understand the molecular mechanisms that lead to the polymerization of the microtubule-associated protein tau into pathological structures observed in Alzheimer's disease and other neurodegenerative disorders. The main thrust of research will involve the detailed investigation of the effects of tau phosphorylation on its ability to polymerize, bind microtubules, and stabilize microtubules. This research will be accomplished using several molecular biology and biochemical approaches, including site-directed mutagenesis, laser light scattering, electron microscopy, and in vitro binding assays.

 

Teaching Interests

  • Biochemistry
  • Neurobiology
  • Cell biology

Research Interests

  • Neurodegeneration
  • Alzheimer's disease
  • Biochemistry

Selected Publications

Paranjape, S. R., Riley, A. P., Somoza, A. D., Oakley, C. E., Wang, C. C., Prisinzano, T. E., Oakley, B. R., & Gamblin, T. C. (2015). Azaphilones Inhibit Tau Aggregation and Dissolve Tau Aggregates in Vitro. ACS chemical neuroscience. DOI:10.1021/acschemneuro.5b00013

Paranjape, S. R., Chiang, Y. M., Sanchez, J. F., Entwistle, R. Wang, C. C., Oakley, B. R., & Gamblin, T. C. (2014). Inhibition of Tau aggregation by three Aspergillus nidulans secondary metabolites: 2,ω-dihydroxyemodin, asperthecin, and asperbenzaldehyde. Planta medica, 80(1), 77-85. DOI:10.1055/s-0033-1360180

Combs, B. & Gamblin, T. C. (2012). FTDP-17 tau mutations induce distinct effects on tau aggregation and microtubule interactions. Biochemistry, 51(43), 8597-8607. DOI:10.1021/bi3010818

Voss, K. Combs, B. Patterson, K. R., Binder, L. I., & Gamblin, T. C. (2012). Hsp70 alters tau function and aggregation in an isoform specific manner. Biochemistry, 51(4), 888-898. DOI:10.1021/bi2018078

Moore, C. L., Huan, M. H., Robbennolt, S. A., Voss, K. R., Combs, B. Gamblin, T. C., & Goux, W. J. (2011). Secondary nucleating sequences affect kinetics and thermodynamics of tau aggregation. Biochemistry, 50(50), 10876-10886. DOI:10.1021/bi2014745

Patterson, K. R., Ward, S. M., Combs, B. Voss, K. Kanaan, N. M., Morfini, G. Brady, S. T., Gamblin, T. C., & Binder, L. I. (2011). Heat shock protein 70 prevents both tau aggregation and the inhibitory effects of preexisting tau aggregates on fast axonal transport. Biochemistry, 50(47), 10300-10310. DOI:10.1021/bi2009147

Combs, B. Voss, K. & Gamblin, T. C. (2011). Pseudohyperphosphorylation has differential effects on polymerization and function of tau isoforms. Biochemistry, 50(44), 9446-9456. DOI:10.1021/bi2010569

Sun, Q. & Gamblin, T. C. (2009). Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization. Biochemistry, 48(25), 6002-6011. DOI:10.1021/bi900602h

Voss, K. & Gamblin, T. C. (2009). GSK-3β phosphorylation of functionally distinct tau isoforms has differential, but mild effects. Molecular Neurodegeneration, 4, 18. DOI:10.1186/1750-1326-4-18

Rankin, C. A., Sun, Q. & Gamblin, T. C. (2008). Pre-assembled tau filaments phosphorylated by GSK-3β form large tangle-like structures. Neurobiology of Disease, 31(3), 368-377.

Rankin, C. A., & Gamblin, T. C. (2008). Assessing the toxicity of tau aggregation. Journal of Alzheimer's Disease, 14(4), 411-416.

Carlson, S. W., Branden, M. Voss, K. Sun, Q. Rankin, C. A., & Gamblin, T. C. (2007). A complex mechanism for inducer mediated tau polymerization. Biochemistry, 46, 8838-8849.

Rankin, C. A., Sun, Q. & Gamblin, T. C. (2007). Tau phosphorylation by GSK3 promotes tangled filament morphology. Molecular Neurodegeneration, 2, 12.

» Show All Publications

Representative Publications

  • Paranjape, S. R., Riley, A. P., Somoza, A. D., Oakley, C. E., Wang, C. C., Prisinzano, T. E., Oakley, B. R., and Gamblin, T. C. (2015) “Azaphilones inhibit tau aggregation and dissolve tau aggregates in vitroACS Chem Neurosci 6(5): 751-760.
  • Paranjape, S. R., Chiang, Y. M., Sanchez, J. F., Entwistle, R., Wang, C. C., Oakley, B. R., and Gamblin T. C. (2014) “Inhibition of Tau aggregation by three Aspergillus nidulans secondary metabolites: 2,ω-dihydroxyemodin, asperthecin and asperbenzaldehyde” Planta Medica 80(1): 77-85.
  • Combs, B. and Gamblin, T. C (2012) “FTDP-17 tau mutations induce highly variable effects on tau aggregation and microtubule interactions” Biochemistry 51 (43): 8597-8607.
  • Voss, K., Combs, B., Patterson, K. R., Binder, L. I. and Gamblin, T. C. (2012) "Hsp70 alters tau function and aggregation in an isoform specific manner" Biochemistry. 2012 Jan 31;51(4):888-98.
  • Moore, C. L., Huang, M. H., Robbennolt, S. A., Voss, K. R, Combs, B., Gamblin,  T. C. and Goux, W. J. (2011) “Secondary Nucleating Sequences Affect Kinetics and Thermodynamics of Tau Aggregation”Biochemistry. 50(50):10876-86.

  • Patterson, K. R., Ward, S. M., Combs, B., Voss, K., Kanaan N. M., Morfini, G., Brady, S. T., Gamblin, T. C., and Binder, L. I. (2011) “Heat Shock Protein 70 Prevents both Tau Aggregation and the Inhibitory Effects of Preexisting Tau Aggregates on Fast Axonal Transport” Biochemistry.  29;50(47):10300-10.

  • Combs, B., Voss, K., and Gamblin, T. C. (2011)“Pseudohyperphosphorylation has differential effects on polymerization and function of tau isoforms” Biochemistry. 50(44):9446-56.

  • Sun, Q. and Gamblin, T. C. (2009) "Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization" Biochemistry. 48(25):6002-11

  • Voss, K. and Gamblin, T. C. (2009 May 2) "GSK-3beta phosphorylation of functionally distinct tau isoforms has differential, but mild effects" Molecular Neurodegeneration, 4:18.

  • Rankin, C. A., Sun, Q., and Gamblin, T. C. (2008) "Pre-assembled tau filaments phosphorylated by GSK-3β form large tangle-like structures" Neurobiology of Disease, 31(3): 368–377.

  • Rankin, C. A. and Gamblin, T. C. (2008) "Assessing the toxicity of tau aggregation" Journal of Alzheimer’s Disease, 14(4): 411–416.

  • Carlson, S.W., Branden, M., Voss, K., Sun, Q., Rankin, C.A., and Gamblin, T. C (2007) "A complex mechanism for inducer mediated tau polymerization"  Biochemistry 46, 8838-8849.

  • Rankin, C. A., Sun, Q., and Gamblin, T. C. (2007) "Tau phosphorylation by GSK3 promotes tangled filament morphology" Molecular Neurodegeneration 2:12

  • Sarthy, J.F, and Gamblin, T.C. (2006) "A light scattering assay for arachidonic acid induced tau fibrillization without interfering micellization" Analytical Biochemistry, 353(1):150–2.

  • Rankin, C.A., Sun, Q., and Gamblin, T.C. (2005) "Pseudo-phosphorylation of tau at Ser 202 and Thr 205 affects tau filament formation" Brain Res Mol Brain Res. 138: 84–93.

  • Gamblin, TC (2005) "Potential structure/function relationships of predicted secondary structural elements of tau" Biochim Biophys Acta. 1739(2-3): 140-9

  • Gamblin, T.C., Chen, F., Zambrano, A., Abraha, A., Lagalwar, S., Guillozet, A.L., Lu, M., Fu, Y., Garcia-Sierra, F., LaPointe, N., Miller, R., Berry, R.W., Binder, L.I., and Cryns, V.L. (2003) "Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease" Proc Natl Acad Sci U S A. 100(17):10032–7.

  • Gamblin, T.C., Berry, R.W., and Binder, L.I. (2003) "Tau polymerization: role of the amino terminus"Biochemistry 42(7):2252–7.

  • Gamblin, T.C., Berry, R.W., and Binder, L.I. (2003) "Modeling tau polymerization in vitro: a review and synthesis"Biochemistry 42:15009–17.

  • Gamblin, T. C., King, M. E., Kuret, J., Berry, R. W., and Binder, L. I. (2000) "Oxidative Regulation of Fatty Acid-Induced Tau Polymerization" Biochemistry 39: 14203–14210.

  • Abraha, A., Ghoshal, N., Gamblin, T. C., Cryns, V., Berry, R. W., Kuret, J., and Binder, L. I. (2000) "C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease" J. Cell Science 113: 3737–3745.

  • Gamblin, T. C., King, M. E., Dawson, H., Vitek, M. P., Kuret, J., Berry, R. W., and Binder, L. I. (2000) "In Vitro Polymerization of Tau Protein Monitored by Laser Light Scattering: Method and Application to the Study of FTDP-17 Mutants" Biochemistry 39: 6136–6144.

  • King, M. E., Gamblin, T. C., Kuret, J., and Binder, L. I. (2000) "Differential assembly of human tau isoforms in the presence of arachidonic acid" J. Neurochemistry 74: 1749–57.

Home to 50+ departments, centers, and programs, the School of the Arts, and the School of Public Affairs and Administration
KU offers courses in 40 languages
No. 1 ranking in city management and urban policy —U.S. News and World Report
One of 34 U.S. public institutions in the prestigious Association of American Universities
44 nationally ranked graduate programs.
—U.S. News & World Report
Top 50 nationwide for size of library collection.
—ALA
23rd nationwide for service to veterans —"Best for Vets," Military Times
KU Today